Iran+ deals will be a bigger market than Saudi Arabia Iran has more than twice the population as KSA and a much more extensive healthcare system that is now growing rapidly with the lifting of embargoes .
Colvalon has been building a base in Iran for several years And recently entered into a distribution agreement to make ALL of its entire product line available for distribution to the Ministry of Health and also the private hospital systems in Iran.
This is a substantial success for Covalon.
Their products now have the opportunity to be category leaders for the Iranium infection and wound care space.
Covalon also has a break through in Qatar where it's flagship advanced wound care product ColActive Plus Ag has been trialled successfully over the past several months in the eight-hospital system managed by Hamad Medical Corp., the main provider of secondary and tertiary health care in Qatar and one of the leading hospital providers in the Middle East.
Covalen expects to immediately introduce its IV Clear, SurgiClear and CovaWound product lines to Hamad Medical's five specialist hospitals and three community hospitals in Qatar.
Covalon has also commenced the process of registering its full product line with SEHA Abu Dhabi Health Services Company, which owns and operates 12 hospitals, 62 ambulatory and primary health care centres, and two blood banks, across the entire United Arab Emirates.
Combined, these three deals have a market potential several times larger than KSA and Covalon's entire product line is being made available in two of these.
Over the next year or so, these three distribution deals will progressively escalate
Covalon's sales..